studies

urothelial cancer (UC) - bladder cancer (BC), durvalumab plus tremelimumab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDANUBE (DT vs C - all population), 2020 0.85 [0.71; 1.01] DANUBE (DT vs C - PDL1>25%), 2020 0.74 [0.59; 0.93] 0.81[0.70; 0.93]DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 202020%1,098moderatenot evaluable progression or deaths (PFS)detailed resultsDANUBE (DT vs C - all population), 2020 1.23 [0.88; 1.72] DANUBE (DT vs C - PDL1>25%), 2020 1.02 [0.62; 1.68] 1.16[0.88; 1.54]DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 202020%1,098moderatenot evaluable DORdetailed resultsDANUBE (DT vs C - all population), 2020 0.44 [0.25; 0.75] DANUBE (DT vs C - PDL1>25%), 2020 0.38 [0.19; 0.75] 0.41[0.27; 0.63]DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 202020%489moderatenot evaluable objective responses (ORR)detailed resultsDANUBE (DT vs C - all population), 2020 0.59 [0.43; 0.80] DANUBE (DT vs C - PDL1>25%), 2020 0.94 [0.64; 1.39] 0.73[0.46; 1.16]DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020271%1,098moderatenot evaluable AE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.55 [0.40; 0.78] 0.55[0.40; 0.78]DANUBE (DT vs C - all population), 202010%653NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsDANUBE (DT vs C - all population), 2020 1.51 [1.02; 2.22] 1.51[1.02; 2.22]DANUBE (DT vs C - all population), 202010%653NAnot evaluable SAE (any grade)detailed resultsDANUBE (DT vs C - all population), 2020 1.67 [1.23; 2.28] 1.67[1.23; 2.28]DANUBE (DT vs C - all population), 202010%653NAnot evaluable STRAE (any grade)detailed resultsDANUBE (DT vs C - all population), 2020 1.57 [1.06; 2.32] 1.57[1.06; 2.32]DANUBE (DT vs C - all population), 202010%653NAnot evaluable TRAE (any grade)detailed resultsDANUBE (DT vs C - all population), 2020 0.32 [0.20; 0.50] 0.32[0.20; 0.50]DANUBE (DT vs C - all population), 202010%653NAnot evaluable TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.25 [0.18; 0.35] 0.25[0.18; 0.35]DANUBE (DT vs C - all population), 202010%653NAnot evaluable TRAE leading to death (grade 5)detailed resultsDANUBE (DT vs C - all population), 2020 1.85 [0.17; 20.46] 1.85[0.17; 20.46]DANUBE (DT vs C - all population), 202010%653NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsDANUBE (DT vs C - all population), 2020 1.30 [0.83; 2.03] 1.30[0.83; 2.03]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 2.78 [0.29; 26.84] 2.78[0.29; 26.84]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31] 7.44[0.39; 141.31]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.02 [0.01; 0.10] 0.02[0.01; 0.10]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 5.56 [0.28; 111.52] 5.56[0.28; 111.52]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Arthritis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.65 [0.20; 2.08] 0.65[0.20; 2.08]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75] 0.46[0.02; 13.75]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31] 7.44[0.39; 141.31]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.69 [0.15; 3.10] 0.69[0.15; 3.10]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.67 [0.56; 5.05] 1.67[0.56; 5.05]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.68 [0.23; 2.00] 0.68[0.23; 2.00]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.30 [0.03; 2.95] 0.30[0.03; 2.95]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Gastritis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75] 0.46[0.02; 13.75]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 5.56 [0.28; 111.52] 5.56[0.28; 111.52]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33] 3.70[0.17; 82.33]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.85 [0.34; 10.18] 1.85[0.34; 10.18]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 2.78 [0.29; 26.84] 2.78[0.29; 26.84]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 15.41 [2.03; 116.88] 15.41[2.03; 116.88]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.04 [0.00; 0.63] 0.04[0.00; 0.63]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.11 [0.01; 0.90] 0.11[0.01; 0.90]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsOut of scaleDANUBE (DT vs C - all population), 2020 0.01 [0.00; 0.09] 0.01[0.00; 0.09]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33] 3.70[0.17; 82.33]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.11 [0.01; 2.16] 0.11[0.01; 2.16]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33] 3.70[0.17; 82.33]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.13; 6.57] 0.92[0.13; 6.57]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Rash TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31] 7.44[0.39; 141.31]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75] 0.46[0.02; 13.75]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53] 0.92[0.02; 46.53]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.02 [0.00; 0.29] 0.02[0.00; 0.29]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15] 1.84[0.06; 55.15]DANUBE (DT vs C - all population), 202010%653NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsDANUBE (DT vs C - all population), 2020 0.36 [0.07; 1.89] 0.36[0.07; 1.89]DANUBE (DT vs C - all population), 202010%653NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-02 10:17 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237 - treatments: 634,861

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons